ATOSSA THERAPEUTICS, INC. Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount
ATOSSA THERAPEUTICS, INC. (ATOS) reported Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount · last filed 2026-03-25
- ATOSSA THERAPEUTICS, INC. equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2025-12-31 was $0.00.
- ATOSSA THERAPEUTICS, INC. equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- ATOSSA THERAPEUTICS, INC. equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2024-12-31 was $0.00.
- ATOSSA THERAPEUTICS, INC. equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2024-09-30 was $1.71M.
- ATOSSA THERAPEUTICS, INC. equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- ATOSSA THERAPEUTICS, INC. equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2024 was $1.71M, a 42.81% decline from fiscal 2023.
- ATOSSA THERAPEUTICS, INC. equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2023 was $2.99M.
- ATOSSA THERAPEUTICS, INC. equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2022 was $0.00.
| Period end | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 3 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 6 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 9 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $0.00 derived: sum of 2 quarters · filed 2026-03-25 | $0.00 10-K · filed 2026-03-25 | |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-12 | $0.00 10-Q · filed 2025-11-12 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $1.71M derived: sum of 2 quarters · filed 2026-03-25 | $1.71M derived: sum of 3 quarters · filed 2026-03-25 | $1.71M 10-K · filed 2026-03-25 |
| 2024-09-30 | $1.71M 10-Q · filed 2025-11-12 | $1.71M derived: sum of 2 quarters · filed 2025-11-12 | $1.71M 10-Q · filed 2025-11-12 | $1.71M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-12 | $0.00 10-Q · filed 2024-08-12 | $0.00 derived: sum of 3 quarters · filed 2025-03-25 | $0.00 derived: sum of 4 quarters · filed 2025-03-25 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-13 | $0.00 derived: sum of 2 quarters · filed 2025-03-25 | $0.00 derived: sum of 3 quarters · filed 2025-03-25 | $2.99M derived: sum of 4 quarters · filed 2025-03-25 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $0.00 derived: sum of 2 quarters · filed 2025-03-25 | $2.99M derived: sum of 3 quarters · filed 2025-03-25 | $2.99M 10-K · filed 2025-03-25 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-12 | $2.99M derived: sum of 2 quarters · filed 2024-11-12 | $2.99M 10-Q · filed 2024-11-12 | $2.99M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $2.99M 10-Q · filed 2024-08-12 | $2.99M 10-Q · filed 2024-08-12 | $2.99M derived: sum of 3 quarters · filed 2024-08-12 | $2.99M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-13 | $0.00 derived: sum of 2 quarters · filed 2024-05-13 | $0.00 derived: sum of 3 quarters · filed 2024-05-13 | $0.00 derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $0.00 derived: sum of 2 quarters · filed 2024-04-01 | $0.00 derived: sum of 3 quarters · filed 2024-04-01 | $0.00 10-K · filed 2024-04-01 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-13 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | $0.00 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-14 | $0.00 10-Q · filed 2023-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |